Raj Kumar Thapa, Kushal Shrestha, Kanchan K. C., Sirapa Maharjan, Shashwot Sedhain, Reshu B. K., Sitaram Khadka
{"title":"改变生活方式的糖尿病前期患者与口服降糖药患者HbA1c水平的比较研究","authors":"Raj Kumar Thapa, Kushal Shrestha, Kanchan K. C., Sirapa Maharjan, Shashwot Sedhain, Reshu B. K., Sitaram Khadka","doi":"10.1155/jcpt/9947273","DOIUrl":null,"url":null,"abstract":"<div>\n <p><b>Background:</b> Lifestyle modifications are the cornerstone of prediabetes management, aiming to prevent or delay progression to diabetes. In addition to lifestyle interventions, pharmacologic treatment with oral hypoglycemic agents (OHAs), particularly metformin, is frequently considered.</p>\n <p><b>Objectives:</b> The objective of this study was to identify optimal strategies for the management of prediabetes in low- and middle-income countries (LMICs) like Nepal.</p>\n <p><b>Methods:</b> A comparative experimental study was conducted to assess the effects of lifestyle modification and treatment with OHA separately in prediabetic patients (16 per group). The lifestyle modification group (Group A) received structured counseling on dietary modifications and physical activity, and the OHA group (Group B) was prescribed metformin. Baseline parameters were recorded for all participants, and blood pressure and HbA1c levels were reassessed at 90 days to determine changes from the baseline.</p>\n <p><b>Results:</b> Significant reduction in HbA1c was observed for both the OHA group (<i>p</i> = 0.0034) and the lifestyle modification group (<i>p</i> < 0.001). The lifestyle modification group achieved significantly greater reductions in HbA1c compared with the OHA group (<i>p</i> = 0.0002).</p>\n <p><b>Conclusions:</b> Lifestyle modification and pharmacological therapy with metformin can lead to a significant decrease in HbA1c levels in the prediabetic population as a sole intervention. Lifestyle modification resulting in greater reduction could be a sustainable and cost-effective alternative, particularly in LMICs like Nepal.</p>\n </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/9947273","citationCount":"0","resultStr":"{\"title\":\"A Comparative Study of the HbA1c Level in Prediabetic Patients With Lifestyle Modification Versus Oral Hypoglycemic Agents\",\"authors\":\"Raj Kumar Thapa, Kushal Shrestha, Kanchan K. C., Sirapa Maharjan, Shashwot Sedhain, Reshu B. K., Sitaram Khadka\",\"doi\":\"10.1155/jcpt/9947273\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n <p><b>Background:</b> Lifestyle modifications are the cornerstone of prediabetes management, aiming to prevent or delay progression to diabetes. In addition to lifestyle interventions, pharmacologic treatment with oral hypoglycemic agents (OHAs), particularly metformin, is frequently considered.</p>\\n <p><b>Objectives:</b> The objective of this study was to identify optimal strategies for the management of prediabetes in low- and middle-income countries (LMICs) like Nepal.</p>\\n <p><b>Methods:</b> A comparative experimental study was conducted to assess the effects of lifestyle modification and treatment with OHA separately in prediabetic patients (16 per group). The lifestyle modification group (Group A) received structured counseling on dietary modifications and physical activity, and the OHA group (Group B) was prescribed metformin. Baseline parameters were recorded for all participants, and blood pressure and HbA1c levels were reassessed at 90 days to determine changes from the baseline.</p>\\n <p><b>Results:</b> Significant reduction in HbA1c was observed for both the OHA group (<i>p</i> = 0.0034) and the lifestyle modification group (<i>p</i> < 0.001). The lifestyle modification group achieved significantly greater reductions in HbA1c compared with the OHA group (<i>p</i> = 0.0002).</p>\\n <p><b>Conclusions:</b> Lifestyle modification and pharmacological therapy with metformin can lead to a significant decrease in HbA1c levels in the prediabetic population as a sole intervention. Lifestyle modification resulting in greater reduction could be a sustainable and cost-effective alternative, particularly in LMICs like Nepal.</p>\\n </div>\",\"PeriodicalId\":15381,\"journal\":{\"name\":\"Journal of Clinical Pharmacy and Therapeutics\",\"volume\":\"2025 1\",\"pages\":\"\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-07-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/9947273\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Pharmacy and Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/jcpt/9947273\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Pharmacy and Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/jcpt/9947273","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
A Comparative Study of the HbA1c Level in Prediabetic Patients With Lifestyle Modification Versus Oral Hypoglycemic Agents
Background: Lifestyle modifications are the cornerstone of prediabetes management, aiming to prevent or delay progression to diabetes. In addition to lifestyle interventions, pharmacologic treatment with oral hypoglycemic agents (OHAs), particularly metformin, is frequently considered.
Objectives: The objective of this study was to identify optimal strategies for the management of prediabetes in low- and middle-income countries (LMICs) like Nepal.
Methods: A comparative experimental study was conducted to assess the effects of lifestyle modification and treatment with OHA separately in prediabetic patients (16 per group). The lifestyle modification group (Group A) received structured counseling on dietary modifications and physical activity, and the OHA group (Group B) was prescribed metformin. Baseline parameters were recorded for all participants, and blood pressure and HbA1c levels were reassessed at 90 days to determine changes from the baseline.
Results: Significant reduction in HbA1c was observed for both the OHA group (p = 0.0034) and the lifestyle modification group (p < 0.001). The lifestyle modification group achieved significantly greater reductions in HbA1c compared with the OHA group (p = 0.0002).
Conclusions: Lifestyle modification and pharmacological therapy with metformin can lead to a significant decrease in HbA1c levels in the prediabetic population as a sole intervention. Lifestyle modification resulting in greater reduction could be a sustainable and cost-effective alternative, particularly in LMICs like Nepal.
期刊介绍:
The Journal of Clinical Pharmacy and Therapeutics provides a forum for clinicians, pharmacists and pharmacologists to explore and report on issues of common interest. Reports and commentaries on current issues in medical and pharmaceutical practice are encouraged. Papers on evidence-based clinical practice and multidisciplinary collaborative work are particularly welcome. Regular sections in the journal include: editorials, commentaries, reviews (including systematic overviews and meta-analyses), original research and reports, and book reviews. Its scope embraces all aspects of clinical drug development and therapeutics, including:
Rational therapeutics
Evidence-based practice
Safety, cost-effectiveness and clinical efficacy of drugs
Drug interactions
Clinical impact of drug formulations
Pharmacogenetics
Personalised, stratified and translational medicine
Clinical pharmacokinetics.